D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients

Leukemia. 2005 Dec;19(12):2332-3; author reply 2333-4. doi: 10.1038/sj.leu.2403993.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Benzamides
  • Drug Resistance, Neoplasm / genetics*
  • Fatal Outcome
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Mutation, Missense*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Prognosis
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate